Guardian Pharmacy Services Projects 2026 Adjusted EBITDA Growth to $115–$118 Million

Reuters01-14

<a href="https://laohu8.com/S/GRDN">Guardian Pharmacy</a> Services Projects 2026 Adjusted EBITDA Growth to $115–$118 Million

Guardian Pharmacy Services Inc. has reiterated its 2025 financial guidance, projecting revenue between $1.43 billion and $1.45 billion and adjusted EBITDA of $104 million to $106 million. For 2026, the company expects revenue to range from $1.40 billion to $1.42 billion, reflecting the anticipated effects of drug pricing reforms and wholesale acquisition cost reductions. Despite the slight decrease in projected revenue for 2026, Guardian anticipates adjusted EBITDA to grow to $115 million to $118 million, representing approximately 11% year-over-year growth and a structural improvement in adjusted EBITDA margin to above 8%. The company attributes this continued low double-digit adjusted EBITDA growth trajectory to its strengthened operating model and recent business initiatives, including the acquisition of a pharmacy location in Montana.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardian Pharmacy Services Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-011826), on January 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603653819?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 05:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603653819","market":"us","top_or_hot":-1,"title":"Guardian Pharmacy Services Projects 2026 Adjusted EBITDA Growth to $115–$118 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GRDN\">Guardian Pharmacy</a> Services Projects 2026 Adjusted EBITDA Growth to $115–$118 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Guardian Pharmacy Services Inc. has reiterated its 2025 financial guidance, projecting revenue between $1.43 billion and $1.45 billion and adjusted EBITDA of $104 million to $106 million. For 2026, the company expects revenue to range from $1.40 billion to $1.42 billion, reflecting the anticipated effects of drug pricing reforms and wholesale acquisition cost reductions. Despite the slight decrease in projected revenue for 2026, Guardian anticipates adjusted EBITDA to grow to $115 million to $118 million, representing approximately 11% year-over-year growth and a structural improvement in adjusted EBITDA margin to above 8%. The company attributes this continued low double-digit adjusted EBITDA growth trajectory to its strengthened operating model and recent business initiatives, including the acquisition of a pharmacy location in Montana.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardian Pharmacy Services Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-011826), on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardian Pharmacy Services Projects 2026 Adjusted EBITDA Growth to $115–$118 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardian Pharmacy Services Projects 2026 Adjusted EBITDA Growth to $115–$118 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-14 05:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GRDN\">Guardian Pharmacy</a> Services Projects 2026 Adjusted EBITDA Growth to $115–$118 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Guardian Pharmacy Services Inc. has reiterated its 2025 financial guidance, projecting revenue between $1.43 billion and $1.45 billion and adjusted EBITDA of $104 million to $106 million. For 2026, the company expects revenue to range from $1.40 billion to $1.42 billion, reflecting the anticipated effects of drug pricing reforms and wholesale acquisition cost reductions. Despite the slight decrease in projected revenue for 2026, Guardian anticipates adjusted EBITDA to grow to $115 million to $118 million, representing approximately 11% year-over-year growth and a structural improvement in adjusted EBITDA margin to above 8%. The company attributes this continued low double-digit adjusted EBITDA growth trajectory to its strengthened operating model and recent business initiatives, including the acquisition of a pharmacy location in Montana.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardian Pharmacy Services Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-011826), on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4128","symbol_name":"药品零售","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDLbBGQ4S:1","article_id":"2603653819","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603653819","pubTimestamp":1768340557,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Guardian Pharmacy Services Inc. has reiterated its 2025 financial guidance, projecting revenue between $1.43 billion and $1.45 billion and adjusted EBITDA of $104 million to $106 million. For 2026, the company expects revenue to range from $1.40 billion to $1.42 billion, reflecting the anticipated effects of drug pricing reforms and wholesale acquisition cost reductions. Despite the slight decrease in projected revenue for 2026, Guardian anticipates adjusted EBITDA to grow to $115 million to $118 million, representing approximately 11% year-over-year growth and a structural improvement in adjusted EBITDA margin to above 8%. The company attributes this continued low double-digit adjusted EBITDA growth trajectory to its strengthened operating model and recent business initiatives, including the acquisition of a pharmacy location in Montana.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4128":"药品零售","BK4196":"保健护理服务","GRDN":"Guardian Pharmacy Services, Inc."},"translate_title":"Guardian Pharmacy Services预计2026年调整后EBITDA增长至115-1.18亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRDN":0.9},"content_text":"Guardian Pharmacy Services Projects 2026 Adjusted EBITDA Growth to $115–$118 Million\n    \n\n        Guardian Pharmacy Services Inc. has reiterated its 2025 financial guidance, projecting revenue between $1.43 billion and $1.45 billion and adjusted EBITDA of $104 million to $106 million. For 2026, the company expects revenue to range from $1.40 billion to $1.42 billion, reflecting the anticipated effects of drug pricing reforms and wholesale acquisition cost reductions. Despite the slight decrease in projected revenue for 2026, Guardian anticipates adjusted EBITDA to grow to $115 million to $118 million, representing approximately 11% year-over-year growth and a structural improvement in adjusted EBITDA margin to above 8%. The company attributes this continued low double-digit adjusted EBITDA growth trajectory to its strengthened operating model and recent business initiatives, including the acquisition of a pharmacy location in Montana.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardian Pharmacy Services Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-011826), on January 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603653819","isCrawlerRequest":true}